Table 2.

Non-BCMA-directed ADCs in Active Clinical Trials for RRMM.

Drug	Target	Trial ID (References)	Payload
STI-6129	CD38	NCT05308225 [85]	Duostatin-5.2 (MMAF derivative; tubulin inhibitor)
Modakafusp alfa (TAK-573)	CD38	NCT03215030 [86]	Interferon alfa 2b (attenuated form)
MT-169 (TAK-169)	CD38	NCT04017130 [87]	Ribosome-inactivating Shiga-like toxin-A subunit
FOR46	CD46	NCT03650491 [88]	MMAE
Indatuximab ravtansine (BT-062)	CD138	NCT01638936 [89]	DM4 (antitubulin maytansinoid)
LM-305	GPRC5D	NCT05647512 [90]	NA
STRO-001	CD74	NCT03424603 [91,92]	Maytansinoid (chemistry not disclosed)

MMAE = monomethylauristatin E; MMAF = monomethylauristatin F; NA = information not available.